Investor's Business Daily on MSN
Gilead bounds higher as analysts debate the future of its potential HIV blockbuster
Gilead stock reversed higher Wednesday after beating fourth-quarter expectations and issuing strong guidance for Yeztugo.
Zacks Investment Research on MSN
Ahead of Gilead (GILD) Q4 earnings: Get ready with Wall Street estimates for key metrics
In its upcoming report, Gilead Sciences (GILD) is predicted by Wall Street analysts to post quarterly earnings of $1.83 per share, reflecting a decline of 3.7% compared to the same period last year.
Antiviral pioneer Gilead Sciences is expected to report fourth-quarter earnings results on Tuesday after the closing bell. A Zacks Rank #3 (Hold) stock, Gilead surpassed earnings estimates in three ...
Biotech leader Gilead Sciences GILD made headlines on Wednesday, with its stock spiking nearly 6% after delivering favorable Q4 results yesterday evening. Thanks to its durable drug pipeline for HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results